Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
:1801
Total Valuation
Innovent Biologics has a market cap or net worth of HK$165.11B. The enterprise value is HK$126.14B.
Market CapHK$165.11B
Enterprise ValueHK$126.14B
Share Statistics
Innovent Biologics has 1,712,744,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,712,744,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Innovent Biologics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -5.16%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-5.16%
Return on Capital Employed (ROCE)-0.04
Revenue Per Employee1.66M
Profits Per Employee-13.89K
Employee Count5,659
Asset Turnover0.44
Inventory Turnover1.84
Valuation Ratios
The current PE Ratio of Innovent Biologics is 129.8. Innovent Biologics’s PEG ratio is 6.48.
PE Ratio129.8
PS Ratio5.94
PB Ratio4.26
Price to Fair Value4.26
Price to FCF-133.71
Price to Operating Cash Flow99.87
PEG Ratio6.48
Income Statement
In the last 12 months, Innovent Biologics had revenue of 9.42B and earned -94.63M in profits. Earnings per share was -0.06.
Revenue9.42B
Gross Profit7.91B
Operating Income-755.87M
Pretax Income-78.62M
Net Income-94.63M
EBITDA-480.28M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was 1.50B and capital expenditures -266.15M, giving a free cash flow of 1.24B billion.
Operating Cash Flow1.50B
Free Cash Flow1.24B
Free Cash Flow per Share0.72
Dividends & Yields
Innovent Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change119.39%
50-Day Moving Average96.46
200-Day Moving Average62.91
Relative Strength Index (RSI)57.68
Average Volume (3m)19.87M
Important Dates
Innovent Biologics upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateAug 27, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Innovent Biologics as a current ratio of 2.35, with Debt / Equity ratio of 23.43%
Current Ratio2.35
Quick Ratio2.16
Debt to Market Cap0.05
Net Debt to EBITDA9.74
Interest Coverage Ratio-11.17
Taxes
In the past 12 months, Innovent Biologics has paid 16.01M in taxes.
Income Tax16.01M
Effective Tax Rate-0.20
Enterprise Valuation
Innovent Biologics EV to EBITDA ratio is -106.74, with an EV/FCF ratio of -122.53.
EV to Sales5.44
EV to EBITDA-106.74
EV to Free Cash Flow-122.53
EV to Operating Cash Flow39.83
Balance Sheet
Innovent Biologics has HK$9.54B in cash and marketable securities with HK$3.38B in debt, giving a net cash position of HK$6.16B billion.
Cash & Marketable SecuritiesHK$9.54B
Total DebtHK$3.38B
Net CashHK$6.16B
Net Cash Per ShareHK$3.60
Tangible Book Value Per ShareHK$7.27
Margins
Gross margin is 76.34%, with operating margin of -8.02%, and net profit margin of -1.00%.
Gross Margin76.34%
Operating Margin-8.02%
Pretax Margin-0.83%
Net Profit Margin-1.00%
EBITDA Margin-5.10%
EBIT Margin-8.02%
Analyst Forecast
The average price target for Innovent Biologics is HK$107.77, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$107.77
Price Target Upside7.02% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast52.78%
EPS Growth Forecast―